The Hepatitis C Transplant Collaborative
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorBaylor Research Institute
About this trial
In this study we seek to test the hypothesis that safety and clinical outcomes after cardiac transplantation utilizing HCV NAT+ donor organs as currently performed are acceptable.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Recipient of a proven HCV NAT+ donor heart.
Re-transplant patients will be included.
Disqualifiers
None
Trial population
Cardiac transplant recipients utilizing HCV NAT+ donor organs
Trial design
Design model
Cohort
Time perspective
Retrospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Number of donor HCV nucleic-acid testing positive (HCV NAT+) cardiac transplantation
To assess the current status of donor HCV NAT+ cardiac transplantation via retrospective data collection.
Time frame
6.5 years2
Failure versus Cure Rate for HCV NAT+ Heart Transplants
sustained viral response (SVR)-12 (cure-rate) for HCV negative recipient
Time frame
6.5 years3
Rate of Primary graft dysfunction (PGD)
Rate of Expected Post-Transplant Risks
Time frame
30 days4
1 year mortality
Number of deaths
Time frame
1 YearSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov